2021 Volume 33 Issue 3 Pages 198-206
[Objective] We evaluated the effectiveness and safety of sarilumab in rheumatoid arthritis（RA）in clinical practice.
[Methods] Thirty-five RA patients who initiated sarilumab from February 2018 to September 2019 were enrolled, and we reviewed the change of clinical disease activity index（CDAI）, and safety for 24 weeks after initiation of sarilumab retrospectively.
[Results] Mean age was 60.3 ± 17.5 years old, duration of RA was 12.5 ± 9.3 years, CDAI was 26.2 ± 10.8, concomitant use of methotrexate（MTX）was 62.9% at baseline. Six patients were biologic and Janus kinase inhibitor-naïve, and 29 patients had been experienced at least one biologic or targeted synthetic disease-modifying antirheumatic drugs. CDAI rapidly decreased to 17.2 at two weeks, and finally decreased to 10.9 ± 9.2 at 24 weeks. The effectiveness of sarilumab was not changed in patients without concomitant use of MTX or in patients whose treatment were switched from tocilizumab. Body mass index（BMI）did not influence treatment response to sarilumab. There were seven adverse events. The most common of them were infections. The number of patients who discontinued sarilumab was nine. The most common reason was ineffectiveness.
